# US 2025/0144117 A1 · Iloprost compositions and formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144117 A1
- Document ID: US20250144117A1
- Status: Published application
- Kind: A1
- Application number: 19/018,702
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2020-08-07
- Assignees: BTG International Limited
- Applicants: Btg International Inc.
- Inventors: Wade W. BENTON; Kevin A. CHRISTAL
- Web page: https://patentgrep.com/patent/US20250144117A1

## CPC

- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61P 19/04: for non-specific disorders of the connective tissue
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A pharmaceutical composition, comprising:
i. about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
iii. sodium chloride; and
iv. ethanol.

### Claim 45

A pharmaceutical composition, comprising:
i. about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
iii. about 9.0 mg/mL of sodium chloride, relative to a total volume of the composition; and
iv. ethanol.

### Claim 46

A pharmaceutical composition, comprising:
i about 0.1 mg/mL of iloprost, or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, relative to a total volume of the composition;
ii. about 0.24 mg/mL of tromethamine, relative to a total volume of the composition;
iii. about 9.0 mg/mL of sodium chloride, relative to a total volume of the composition; and
iv. ethanol;
wherein the composition has a pH of about 8 to about 9.

### Claim 47 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition is provided as a single-use vial, and wherein each single use vial contains about 1 mL of the composition.

### Claim 48 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition comprises about 0.242 mg/mL of tromethamine, relative to a total volume of the composition.

### Claim 49 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition has a pH of about 8 to about 9.

### Claim 50 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition is formulated as a sterile solution.

### Claim 51 (depends on 44)

The pharmaceutical composition of claim 44, wherein the composition comprises no preservatives.

### Claim 52 (depends on 44)

A pharmaceutical formulation, comprising:
the pharmaceutical composition of claims 44; and
0.9% sodium chloride injection.

### Claim 53 (depends on 44)

A pharmaceutical formulation, comprising:
the pharmaceutical composition of claims 44; and
0.9% sodium chloride injection;
wherein the pharmaceutical formulation comprises about 1 μg/mL of iloprost, or a pharmaceutically acceptable salt or a stereoisomer thereof, relative to a total volume of the composition.

### Claim 54 (depends on 53)

The pharmaceutical formulation of claim 53, wherein the formulation comprises:
about 1 mL of the pharmaceutical composition; and
about 100 mL of the 0.9% sodium chloride injection.

### Claim 55 (depends on 54)

The pharmaceutical formulation of claim 54, wherein the formulation is stable for up to 4 hours at 20° C. to 25° C.

### Claim 56 (depends on 54)

The pharmaceutical formulation of claim 54, wherein the formulation is for intravenous infusion.

### Claim 57 (depends on 47)

A kit, comprising:
the pharmaceutical composition of claim 47; and
an IV bag comprising of 0.9% sodium chloride injection.

### Claim 58 (depends on 57)

The kit of claim 57, wherein the IV bag comprises about 100 mL of the 0.9% sodium chloride injection.

### Claim 59 (depends on 57)

The kit of claim 57, wherein the IV bag is made of polyvinyl chloride (PVC).
